{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT04018131",
      "orgStudyIdInfo": {
        "id": "0071"
      },
      "organization": {
        "fullName": "Fakultas Kedokteran Universitas Indonesia",
        "class": "OTHER"
      },
      "briefTitle": "The Efficacy of Cimetidin for Acute - Extrinsic Atopic Dermatitis Treated With Standard Therapy",
      "officialTitle": "The Efficacy of Cimetidin for Acute - Extrinsic Atopic Dermatitis Treated With Standard Therapy, a Study of Immunoglobulin E, Interleukin-4, Interleukin-12, and Interferon-Ɣ Serum Levels"
    },
    "statusModule": {
      "statusVerifiedDate": "2019-10",
      "overallStatus": "UNKNOWN",
      "lastKnownStatus": "RECRUITING",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2018-03-26",
        "type": "ACTUAL"
      },
      "primaryCompletionDateStruct": {
        "date": "2020-03-30",
        "type": "ESTIMATED"
      },
      "completionDateStruct": {
        "date": "2020-06-30",
        "type": "ESTIMATED"
      },
      "studyFirstSubmitDate": "2019-07-10",
      "studyFirstSubmitQcDate": "2019-07-11",
      "studyFirstPostDateStruct": {
        "date": "2019-07-12",
        "type": "ACTUAL"
      },
      "lastUpdateSubmitDate": "2019-10-02",
      "lastUpdatePostDateStruct": {
        "date": "2019-10-04",
        "type": "ACTUAL"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "SPONSOR"
      },
      "leadSponsor": {
        "name": "Fakultas Kedokteran Universitas Indonesia",
        "class": "OTHER"
      }
    },
    "oversightModule": {
      "oversightHasDmc": false,
      "isFdaRegulatedDrug": false,
      "isFdaRegulatedDevice": false,
      "isUsExport": false
    },
    "descriptionModule": {
      "briefSummary": "Extrinsic - atopic dermatitis is characterized by increased of IgE serum levels. Acute extrinsic - atopic dermatitis is a type 1 hypersensitivity that involve various inflammatory mediator including Interleukin-4, Interleukin-12, and Interferon-Ɣ. Recent treatment of atopic dermatitis mainly focused on reducing the inflammation through topical and systemic regiments. However, no systemic medication could control the atopic dermatitis remission yet, and the current immunosuppressive agent used may cause many side effects if administered on a long term basis.\n\nIn the future, treatment of atopic dermatitis were specifically targeted to inhibit the role of Th2. Cimetidine is H2 receptor antihistamine that has been widely used as gastrointestinal medication for a long time. Cimetidine could modulate the immune system by activating the Th1 and lowering the Th2 activity, and lowering the IgE levels thus reducing the severity of atopic dermatitis.",
      "detailedDescription": "The aim of this study is to measure the efficacy of cimetidine for acute, extrinsic-atopic dermatitis treated with standard therapy using SCORAD as the clinical outcome. This study also measure Immunoglobulin E, Interleukin-4, Interleukin-12, and Interferon-Ɣ serum levels before and after treatment."
    },
    "conditionsModule": {
      "conditions": [
        "Atopic Dermatitis",
        "Immunoglobulin E Concentration, Serum"
      ],
      "keywords": [
        "Atopic Dermatitis",
        "Cimetidine",
        "Immunoglobulin E",
        "Interleukin-4",
        "Interleukin-12",
        "Interferon Gamma",
        "SCORAD",
        "Treatment"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "designInfo": {
        "allocation": "RANDOMIZED",
        "interventionModel": "PARALLEL",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "QUADRUPLE",
          "whoMasked": [
            "PARTICIPANT",
            "CARE_PROVIDER",
            "INVESTIGATOR",
            "OUTCOMES_ASSESSOR"
          ]
        }
      },
      "enrollmentInfo": {
        "count": 26,
        "type": "ESTIMATED"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "Cimetidine",
          "type": "ACTIVE_COMPARATOR",
          "interventionNames": [
            "Drug: Cimetidine"
          ]
        },
        {
          "label": "Placebo",
          "type": "PLACEBO_COMPARATOR",
          "interventionNames": [
            "Drug: Placebos"
          ]
        }
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "Cimetidine",
          "description": "Antihistamine 2 antagonist",
          "armGroupLabels": [
            "Cimetidine"
          ]
        },
        {
          "type": "DRUG",
          "name": "Placebos",
          "description": "Placebo drug",
          "armGroupLabels": [
            "Placebo"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "SCORAD change",
          "description": "Scoring Atopic Dermatitis (SCORAD) is a score to indicate the severity of atopic dermatitis.\n\nThe minimum score is 0, maximum score is 103. Mild 0 - 14 Moderate 15 - 39 Severe 40 - 103\n\nThe SCORAD before treatment was expected to be higher than after treatment. Outcome: change of SCORAD",
          "timeFrame": "0, 2, 4, 6, 8 weeks"
        },
        {
          "measure": "Immunoglobulin E change",
          "description": "Change of Immunoglobulin E",
          "timeFrame": "0, 8 weeks"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Interleukin-4 change",
          "description": "Change of Interleukin-4",
          "timeFrame": "0, 8 weeks"
        },
        {
          "measure": "Interleukin-12 change",
          "description": "Change of Interleukin-12",
          "timeFrame": "0, 8 weeks"
        },
        {
          "measure": "Interferon Gamma change",
          "description": "Change of Interferon Gamma",
          "timeFrame": "0, 8 weeks"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n* Atopic dermatitis patients diagnosed with Hanifin Rajka criteria\n* Acute extrinsic atopic dermatitis\n* IgE levels above 200 IU/mL\n* Minimum weight 15kg\n\nExclusion Criteria:\n\n* Consumption of corticosteroid and systemic immunosuppressant within the last 2 weeks\n* Chronic lesion\n* Consumption of drugs that reacts with cimetidine\n* Disturbance in lab results including complete blood count, liver function, and renal function.\n* Other conditions that might increase IgE levels",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "12 Years",
      "maximumAge": "60 Years",
      "stdAges": [
        "CHILD",
        "ADULT"
      ]
    },
    "contactsLocationsModule": {
      "centralContacts": [
        {
          "name": "Endi Novianto",
          "role": "CONTACT",
          "phone": "+628161309063",
          "email": "drendinovianto@gmail.com"
        }
      ],
      "locations": [
        {
          "facility": "Faculty of Medicine Universitas Indonesia",
          "status": "RECRUITING",
          "city": "Jakarta Pusat",
          "state": "Jakarta Special Capital Region",
          "zip": "10430",
          "country": "Indonesia",
          "contacts": [
            {
              "name": "Endi Novianto, MD",
              "role": "CONTACT",
              "phone": "+628161309063",
              "email": "drendinovianto@gmail.com"
            }
          ],
          "geoPoint": {
            "lat": -6.1818,
            "lon": 106.8223
          }
        }
      ]
    },
    "referencesModule": {
      "references": [
        {
          "pmid": "35175572",
          "type": "DERIVED",
          "citation": "Novianto E, Jacoeb TNA, Indriatmi W, Suhendro, Setiabudy R, Setiabudy RD, Abdullah M, Rengganis I, Suwarsa O, Soebaryo RW. Effectiveness of Cimetidine as Adjuvant Therapy in the Treatment of Acute-Extrinsic Atopic Dermatitis: A Double-Blind Randomized Controlled Trial. Dermatol Ther (Heidelb). 2022 Mar;12(3):715-726. doi: 10.1007/s13555-022-00688-z. Epub 2022 Feb 17."
        }
      ]
    },
    "ipdSharingStatementModule": {
      "ipdSharing": "NO"
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-04"
    },
    "conditionBrowseModule": {
      "meshes": [
        {
          "id": "D003876",
          "term": "Dermatitis, Atopic"
        }
      ],
      "ancestors": [
        {
          "id": "D012873",
          "term": "Skin Diseases, Genetic"
        },
        {
          "id": "D030342",
          "term": "Genetic Diseases, Inborn"
        },
        {
          "id": "D009358",
          "term": "Congenital, Hereditary, and Neonatal Diseases and Abnormalities"
        },
        {
          "id": "D003872",
          "term": "Dermatitis"
        },
        {
          "id": "D012871",
          "term": "Skin Diseases"
        },
        {
          "id": "D017437",
          "term": "Skin and Connective Tissue Diseases"
        },
        {
          "id": "D017443",
          "term": "Skin Diseases, Eczematous"
        },
        {
          "id": "D006969",
          "term": "Hypersensitivity, Immediate"
        },
        {
          "id": "D006967",
          "term": "Hypersensitivity"
        },
        {
          "id": "D007154",
          "term": "Immune System Diseases"
        }
      ]
    },
    "interventionBrowseModule": {
      "meshes": [
        {
          "id": "D002927",
          "term": "Cimetidine"
        }
      ],
      "ancestors": [
        {
          "id": "D006146",
          "term": "Guanidines"
        },
        {
          "id": "D000578",
          "term": "Amidines"
        },
        {
          "id": "D009930",
          "term": "Organic Chemicals"
        },
        {
          "id": "D007093",
          "term": "Imidazoles"
        },
        {
          "id": "D001393",
          "term": "Azoles"
        },
        {
          "id": "D006573",
          "term": "Heterocyclic Compounds, 1-Ring"
        },
        {
          "id": "D006571",
          "term": "Heterocyclic Compounds"
        }
      ]
    }
  },
  "hasResults": false
}